1. Home
  2. PTLO vs SABS Comparison

PTLO vs SABS Comparison

Compare PTLO & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Portillo's Inc.

PTLO

Portillo's Inc.

HOLD

Current Price

$4.18

Market Cap

323.5M

ML Signal

HOLD

Logo SAB Biotherapeutics Inc.

SABS

SAB Biotherapeutics Inc.

SELL

Current Price

$3.98

Market Cap

288.8M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
PTLO
SABS
Founded
1963
2014
Country
United States
United States
Employees
N/A
86
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
323.5M
288.8M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
PTLO
SABS
Price
$4.18
$3.98
Analyst Decision
Hold
Strong Buy
Analyst Count
11
4
Target Price
$8.06
$10.75
AVG Volume (30 Days)
1.5M
797.3K
Earning Date
05-05-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$732,066,000.00
N/A
Revenue This Year
$9.02
N/A
Revenue Next Year
$5.81
N/A
P/E Ratio
N/A
N/A
Revenue Growth
3.03
N/A
52 Week Low
$3.78
$1.67
52 Week High
$11.82
$6.60

Technical Indicators

Market Signals
Indicator
PTLO
SABS
Relative Strength Index (RSI) 47.51 60.17
Support Level $3.79 $3.48
Resistance Level $4.40 $4.09
Average True Range (ATR) 0.22 0.24
MACD 0.08 0.07
Stochastic Oscillator 60.25 79.12

Price Performance

Historical Comparison
PTLO
SABS

About PTLO Portillo's Inc.

Portillos Inc serves the Chicago street food industry through high-energy and multichannel restaurants designed to ignite the senses and create memorable dining experiences. The company owns and operates fast-casual restaurants in the United States, along with two food production commissaries in Illinois. Its menu includes hot dogs, beef and sausage sandwiches, sandwiches and ribs, salads, burgers, chicken, sides and soup, and others.

About SABS SAB Biotherapeutics Inc.

SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.

Share on Social Networks: